Study overview
The PubMed entry describes a follow-up randomized controlled trial assessing the safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine. The article title explicitly frames the investigation as a non-inferiority trial comparing a reduced booster dose with a reference (presumably standard) dose, and labels the study as single blind and randomized. The record indicates the article is published in Vaccine (2026) and is available as a free article.
The publicly visible metadata on PubMed includes the full author list and institutional affiliations, publication identifiers (PMID and DOI), and publisher citation information. However, the excerpt of the PubMed page provided here does not include the trial abstract text or any numerical or interpretive results.
Trial design and key descriptors
The trial is characterized using these design terms in the PubMed record:
- Single blind — the record labels the follow-up trial as single blinded.
- Randomized — allocation of participants to trial arms is described as randomized.
- Non-inferiority — the primary framework for hypothesis testing is described as non-inferiority.
- Follow-up trial — the study is presented as a follow-up, implying participants had prior exposure, vaccination, or earlier study participation, though specifics are not provided in the source excerpt.
These descriptors identify the trial’s intended methodological framework but the PubMed excerpt does not supply protocol details such as randomization method, blinding procedures, non-inferiority margin, or duration of follow-up.
Authors and institutional affiliations
The PubMed record lists multiple investigators and institutional affiliations. Corresponding institutions and groups named include:
- Sciensano, Scientific Direction Infectious Diseases in Humans (Brussels, Belgium).
- European Plotkin Institute for Vaccinology and U-CRI, Université Libre de Bruxelles (Belgium).
- Virology Unit, Institute of Tropical Medicine (Antwerp, Belgium).
- Laboratory of Enzymology and Protein Folding, Université de Liège (Liège, Belgium).
- Mensura EDPB - Occupational Health Service (Antwerp, Belgium).
- University of Antwerp, Department of Biomedical Sciences (Antwerp, Belgium).
Several authors have electronic contact addresses listed on the PubMed page. These affiliations indicate a multi-institutional Belgian collaboration across public health, vaccinology, virology, and immunology research centers.
Publication and access details
Key citation and access metadata provided on PubMed include:
- Journal: Vaccine.
- Publication year and citation: 2026 Aug 30:89:128897.
- Epub date: 3 July 2026.
- DOI: 10.1016/j.vaccine.2026.128897.
- PubMed Identifier (PMID): 42398210.
- Article type: Randomized Controlled Trial; listed under Vaccine research.
- Access: PubMed lists the article as a free article and provides links to full text options (Elsevier Science link present on the PubMed page).
Available information on outcomes and data gaps
The PubMed page and the provided excerpt identify the study topic and design but do not include the trial abstract or outcome data in the provided text. Specifically, the following key items are not reported in the JINA excerpt and therefore cannot be restated here:
- Sample size and participant demographics (age distribution, sex, comorbidities).
- Eligibility and exclusion criteria for enrollment.
- Exact intervention details (reduced dose amount, schedule, comparator dose).
- Primary and secondary immunogenicity endpoints (assays used, timing of sampling, antibody or cellular measures) and their numerical results.
- Safety outcomes including solicited and unsolicited adverse events, serious adverse events, or reactogenicity rates.
- Non-inferiority margin, statistical analysis plan, and p values or confidence intervals supporting conclusions.
- Trial registration number, funding sources, and conflict of interest declarations beyond the PubMed metadata.
Because these elements are absent from the provided source excerpt, it is not possible to summarize the trial’s efficacy, immunogenicity, or safety findings, to interpret the clinical significance of results, or to assess whether the reduced booster met non-inferiority criteria.
Limitations and recommended next steps
Limitations based on the provided PubMed excerpt:
- The JINA text supplied here is limited to bibliographic metadata, authorship, and general trial descriptors; it omits the abstract and full-text content required to evaluate methods and outcomes.
- Essential trial parameters (dose, endpoints, sample size, numerical results, statistical conclusions) were not available in the supplied text and therefore were not reported or paraphrased here.
Recommended next steps to obtain actionable clinical information:
- Access the full text via the DOI link or publisher site to review the abstract, methods, results, tables, and authors’ conclusions.
- Consult the trial registry entry (if provided in the full text) for protocol details, pre-specified endpoints, and registration timing.
- Review supplementary materials and conflict of interest statements available in the full article to evaluate data completeness and potential biases.
Summary
The PubMed record documents a randomized, single-blind, non-inferiority follow-up trial investigating a reduced homologous booster of the BNT162b2 mRNA COVID-19 vaccine, authored by a multi-institutional Belgian team and published in Vaccine (2026). While metadata and author affiliations are available, the provided source excerpt does not include the trial’s methods, numerical immunogenicity or safety results, non-inferiority conclusions, or other key clinical details. Those specifics must be obtained from the full-text article or the complete PubMed abstract, which were not included in the supplied source material.